Innova Captab LimitedQ1 FY27 Results & Financial Update
Innova Captab Limited: Q1 FY27 consolidated results and company financials – revenue ₹470.85 Cr, PAT ₹44.13 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Innova Captab price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Innova Captab Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Innova Captab Limited delivered consolidated revenue from operations of ₹470.85 crore for the quarter ended 30 June 2026, marking a strong start to FY27 s. Total consolidated income reached ₹472.86 crore, supported by other income of ₹2.01 crore.
According to company earnings presentation disclosures, revenue from operations grew by 34% year-on-year from ₹351.5 crore in Q1 FY26, driven by broad-based performance across both CDMO services and branded generics business areas.
The CDMO Services & Products division remained the primary growth engine, contributing approximately 70% of total revenue with segment sales of ₹328.7 crore, reflecting 32% year-on-year growth. The branded generics business expanded by 39% year-on-year to reach ₹142.2 crore.
Management attributed top-line momentum to steady order flows, a broader product portfolio, deeper customer engagement, and a continuous ramp-up at the newly established Jammu manufacturing facility through existing clients and new onboarding.
The company operates through a single reportable business segment under Ind AS 108 covering drugs and pharmaceutical products. The statutory auditors issued an unmodified review conclusion on the unaudited consolidated and standalone financial results.
01 · Business model
What does Innova Captab do?
Innova Captab Limited operates as a pharmaceutical company with a comprehensive business model spanning Contract Development and Manufacturing Organisation (CDMO) services and products, alongside a domestic and international branded generics business.
The company maintains a broad product portfolio exceeding 4,200 formulations across diverse dosage forms, including oral solids, oral liquids, dry syrups, dry powder injectables, large and small volume parenterals, and ointments.
Manufacturing infrastructure comprises multiple units across Baddi (Himachal Pradesh), Dehradun (Uttarakhand), Taloja (Maharashtra), and a large greenfield multipurpose facility in Kathua (Jammu) commercialized in January 2025.
Innova serves over 350 CDMO customers globally, reaches more than 60 export countries, and maintains a strong domestic distribution network supported by approximately 250,000 touchpoints in India.
02 · Historical context
What shaped the business before this quarter
The company commenced operations in 2006 by establishing its first manufacturing facility in Baddi, Himachal Pradesh, marking its entry into pharmaceutical manufacturing.
Innova expanded its operational capabilities into marketing and distribution through the incorporation of Univentis Medicare Limited in 2015.
The company strengthened its product portfolio and manufacturing footprint through the acquisition of Sharon Bio-Medicine Ltd in June 2023, followed by its initial public offering and stock exchange listing.
Commercial operations at the state-of-the-art multipurpose manufacturing facility in Kathua, Jammu, commenced in January 2025, adding four independent blocks for diverse dosage forms.
Innova secured key quality certifications during 2026, including GMP compliance from UK-MHRA for the Baddi facility and PIC/S (SMDC, Ukraine) certification for the Kathua, Jammu facility.
03 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹470.85 Cr |
| Total income | ₹472.86 Cr |
| Profit before tax | ₹58.99 Cr |
| Profit after tax | ₹44.13 Cr |
| EPS | ₹7.71 |
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
CDMO revenue reached ₹328.7 crore in Q1 FY27, registering a 32% year-on-year increase and contributing approximately 70% of total quarterly revenue.
Branded generics revenue grew by 39% year-on-year to ₹142.2 crore, supported by wider market reach and deeper penetration across domestic and international markets.
The Kathua, Jammu facility contributed to revenue growth through steady operational scaling, higher capacity utilization, and onboarding of new clients following its January 2025 commercialisation.
What drove margins
EBITDA margin remained steady at 16.0% in Q1 FY27 compared to 16.1% in Q1 FY26, reflecting balanced cost absorption despite scaling operations.
Profit after tax margin improved to 9.4% in Q1 FY27 from 8.8% in Q1 FY26, driven by operating leverage and effective financial management.
05 · Demand, customers & order book
Where demand is coming from
Innova serves over 350 CDMO customers globally, including prominent pharmaceutical companies, supported by steady order flows during the quarter.
06 · Segments, products & geography
Which parts of the business are doing the work
Geography and market mix
The company maintains commercial reach across more than 60 export countries alongside a domestic distribution network of over 250,000 touchpoints in India.
07 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
The company operates nine manufacturing blocks across Baddi (3 units), Dehradun (1 unit), Taloja (1 unit), and Kathua, Jammu (4 blocks).
The Jammu plant completed its first full operating year, ramping up utilization from 5%-10% in FY26 toward an optimum target of 70%-75% over 5-6 years, while successfully completing multiple marquee client audits.
Projects, capex and execution
The Kathua, Jammu facility represents a total capital investment exceeding ₹480 crore, featuring four independent blocks for oral solid dosages, dry syrups, large and small volume parenterals, and respiratory respules.
The Jammu facility is eligible for GST-linked incentives totaling up to 300% of investments made in eligible plant and machinery over 10 years, alongside a 6% per annum capital interest subvention on eligible capex loans under the Central Government's New Central Sector Scheme.
08 · Strategy & new businesses
How the company is trying to change its growth mix
Management focuses on maintaining a balanced business model combining CDMO partnerships with an expanding branded generics footprint in domestic and international markets.
09 · Reported developments
What changed operationally
Revenue from operations grew 34% year-on-year to ₹470.9 crore, and EBITDA expanded 33% year-on-year to ₹75.1 crore in Q1 FY27.
Statutory auditors B S R & Co. LLP issued an unmodified review conclusion on both standalone and consolidated unaudited financial results for Q1 FY27.
10 · Pressure points & risks
What is not going smoothly
The company disclosed that subsequent to the approval of FY26 financial statements on May 7, 2026, certain inadvertent errors were identified in group entities' statements, requiring corrections prior to the annual general meeting, though management confirmed no material impact on Q1 FY27 results.
11 · Beyond the numbers
What changed beyond the numbers
Reported update
Materiality Policy Amendment
The board approved amendments to the Policy for Determination of Materiality of Events or Information pursuant to SEBI Listing Regulations updates.
12 · Key Q&A
The quarter, answered directly
What does Innova Captab do?
Innova Captab Limited operates as a pharmaceutical company with a comprehensive business model spanning Contract Development and Manufacturing Organisation (CDMO) services and products, alongside a domestic and international branded generics business.
What is the clearest takeaway from Q1 FY27?
Innova Captab Limited delivered consolidated revenue from operations of ₹470.85 crore for the quarter ended 30 June 2026, marking a strong start to FY27 s. Total consolidated income reached ₹472.86 crore, supported by other income of ₹2.01 crore.
What drove revenue or demand?
CDMO revenue reached ₹328.7 crore in Q1 FY27, registering a 32% year-on-year increase and contributing approximately 70% of total quarterly revenue.
What mattered most for margins or profitability?
EBITDA margin remained steady at 16.0% in Q1 FY27 compared to 16.1% in Q1 FY26, reflecting balanced cost absorption despite scaling operations.
What changed operationally beyond the headline numbers?
The company operates nine manufacturing blocks across Baddi (3 units), Dehradun (1 unit), Taloja (1 unit), and Kathua, Jammu (4 blocks).
What are the main pressure points disclosed for the quarter?
The company disclosed that subsequent to the approval of FY26 financial statements on May 7, 2026, certain inadvertent errors were identified in group entities' statements, requiring corrections prior to the annual general meeting, though management confirmed no material impact on Q1 FY27 results.
13 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
14 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Jammu Facility Ramp-Up: Monitor the continued capacity utilization ramp-up and execution of client orders at the Kathua, Jammu manufacturing plant.
- 02
Annual General Meeting Resolution: Track company disclosures regarding the finalisation and correction process for FY26 financial statements ahead of the ensuing annual general meeting.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.